Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction-Reference-Cited by-同舟云学术

Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction

Published:2021-07-26 Issue:9 Volume:23 Page:1541-1551
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Shah Sanjiv J.¹,Cowie Martin R.²,Wachter Rolf³⁴,Szecsödy Peter⁵,Shi Victor⁶,Ibram Ghionul⁶,Hu Mo¹,Zhao Ziqiang⁷,Gong Jianjian⁶,Pieske Burkert⁸⁹¹⁰

Affiliation:

1. Division of Cardiology, Department of Medicine Northwestern University Feinberg School of Medicine Chicago IL USA

2. School of Cardiovascular Medicine & Sciences, Faculty of Life Sciences & Medicine King's College London London UK

3. Clinic and Policlinic for Cardiology University Hospital Leipzig Leipzig Germany

4. Clinic for Cardiology and Pneumology University Medicine Göttingen and DZHK (German Center for Cardiovascular Research), partner site Göttingen Göttingen Germany

5. Novartis Basel Switzerland

6. Novartis East Hanover NJ USA

7. Novartis Shanghai China

8. Department of Internal Medicine and Cardiology, Campus Virchow Klinikum Charité University Medicine Berlin Germany

9. Department of Internal Medicine and Cardiology German Heart Center; DZHK (German Center for Cardiovascular Research), partner site Berlin Berlin Germany

10. Berlin Institute of Health Berlin Germany

Funder

Novartis

American Heart Association

National Institutes of Health

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2277

Reference36 articles.

1. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

2. Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial

3. U.S. Food and Drug Administration.Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry (Draft Guidance). June 2019.https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/treatment‐heart‐failure‐endpoints‐drug‐development‐guidance‐industry(29 June 2021).

4. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial

5. Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical implication of sarcopenia in patients with acute decompensated heart failure: Design and rationale;ESC Heart Failure;2024-09-03

2. Impact of Panvascular Disease on Exercise Capacity and Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction;CJC Open;2024-09

3. Benefits of sacubitril/valsartan administration and physical training in cardiac rehabilitation: current trends and bibliometric analysis of the years 2015-2024;Balneo and PRM Research Journal;2024-06-21

4. Possibilities of Predicting Peak Oxygen Consumption in Patients With Chronic Heart Failure According to the 6‑Minute Walk Test;Kardiologiia;2024-02-29

5. Quality of life in heart failure: New data, new drugs and devices;Cardiology Journal;2023-09-29